Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ria Mulherkar

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Vaccine|July 15, 2018
In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infectionRia Mulherkar, Aykan Karabudak, Rashida Ginwala, et al.
Cell Death Discovery|July 17, 2023
Inhibition of tyrosine kinase Fgr prevents radiation-induced pulmonary fibrosis (RIPF)Amitava Mukherjee, Michael W Epperly, Renee Fisher, et al.
Brachytherapy|May 2, 2025
Twice daily template-based interstitial brachytherapy for gynecologic cancers: What is the optimal dose?Ria Mulherkar, David Grimm, Paniti Sukumvanich, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Vaccine|July 15, 2018
In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infectionRia Mulherkar, Aykan Karabudak, Rashida Ginwala, et al.
Cell Death Discovery|July 17, 2023
Inhibition of tyrosine kinase Fgr prevents radiation-induced pulmonary fibrosis (RIPF)Amitava Mukherjee, Michael W Epperly, Renee Fisher, et al.
Brachytherapy|May 2, 2025
Twice daily template-based interstitial brachytherapy for gynecologic cancers: What is the optimal dose?Ria Mulherkar, David Grimm, Paniti Sukumvanich, et al.
Pageof 2